Favorable efficacy of long-term lamivudine therapy in patients width chronic hepatitis B: An 8-year follow-up study

Journal of Medical Virology

Volumn 75, Issue 4, 2005, Pages 491-498

  Akuta, Norio ^a   Suzuki, Fumitaka ^a   Suzuki, Yoshiyuki ^a   Sezaki, Hitomi ^a   Hosaka, Tetsuya ^a   Someya, Takashi ^a   Kobayashi, Masahiro ^a   Saitoh, Satoshi ^a   Arase, Yasuji ^a   Ikeda, Kenji ^a   Kobayashi, Mariko ^a   Kumada, Hiromitsu ^a  

^a TORANOMON HOSPITAL   (Japan)

Author keywords

Breakthrough hepatitis; HBsAg clearance; HBV genotype; Hepatocellular carcinoma; YMDD motif mutant

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; JAPAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LONG TERM CARE; MALE; NONHUMAN; PROGNOSIS; RELAPSE; TREATMENT OUTCOME; VIRUS MUTANT;

ADULT; AGED; AMINO ACID MOTIFS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; JAPAN; LAMIVUDINE; MALE; MIDDLE AGED; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 20044384699     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmv.20305     Document Type: Article

References (43)

1. Akuta N, Tsubota A, Suzuki F, Suzuki Y, Hosaka T, Someya T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H. 2003a. Longterm prognosis by lamivudine monotherapy for severe acute exacerbation in chronic hepatitis B infection: Emergence of YMDD motif mutant and risk of breakthrough hepatitis-An open-cohort study. J Hepatol 38:91-97.
2. Akuta N, Suzuki F, Kobayashi M, Tsubota A, Suzuki Y, Hosaka T, Someya T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H. 2003b. The influence of hepatitis B virus genotype on the development of lamivudine resistance during long-term treatment. J Hepatol 38:315-321.
3. Akuta N, Suzuki F, Kobayashi M, Matsuda M, Sato J, Takagi K, Tsubota A, Suzuki Y, Hosaka T, Someya T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H. 2003c. Virological and biochemical relapse according to YMDD motif mutant type during long-term lamivudine monotherapy. J Med Virol 71:504-510.
4. Akuta N, Suzuki F, Kobayashi M, Matsuda M, Sato J, Suzuki Y, Sezaki H, Hosaka T, Someya T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H. 2004. Virological and biochemical relapse after discontinuation of lamivudine monotherapy for chronic hepatitis B in Japan: Comparison with breakthrough hepatitis during long-term treatment. Intervirology (in press).
5. Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL, Brown N, Condreay LD. 1998. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 27:1670-1677.
6. Balzarini J, Wedgwood O, Kruining J, Pelemans H, Heijtink R, De Clercq E, McGuigan C. 1996. Anti-HIV and anti-HBV activity and resistance profile of 2′,3′-dideoxy-3′-thiacytidine (3TC) and its arylphosphoramidate derivative CF 1109. Biochem Biophys Res Commun 2:363-369.
7. Bartholomew MM, Jansen RW, Jeffers LJ, Reddy KR, Johnson LC, Bunzendahal H, Condreay LD, Tzakis AG, Schiff ER, Brown NA. 1997. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 349:20-22.
8. Chayama K, Suzuki Y, Kobayashi M, Kobayashi M, Tsubota A, Hashimoto M, Miyano Y, Koike H, Kobayashi M, Koida I, Arase Y, Saitoh S, Murashima N, Ikeda K, Kumada H. 1998. Emergence and takeover of YMDD motif mutant hepatitis B virus during longterm lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 27:1711-1716.
9. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Sheuer PJ. 1994. Classification of chronic hepatitis: Diagnosis, grading, and staging. Hepatology 19:1513-1520.
10. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. 1995. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 333:1657-1661.
11. Dienstag JL, Sciff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, Crowther L, Condreay LD, Woessner M, Rubin M, Brown NA. 1999. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 341:1256-1263.
12. Dienstag JL, Cianciara J, Karayalcin S, Kowdley KV, Willems B, Plisek S, Woessner M, Gardner S, Schiff ER. 2003. Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology 37:748-755.
13. Doong SL, Tsai CH, Schinazi RF, Liotta DC, Cheng YC. 1991. Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy- 3′-thiacytidine and related analogues. Proc Natl Acad Sci USA 88:8495-8499.
14. Fu L, Cheng YC. 1998. Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC(3TC) resistance. Biochem Pharmacol 55:1567-1572.
15. Honkoop P, Niesters HG, de Man RA, Osterhaus AD, Schalm SW. 1997. Lamivudine resistance in immunocompetent chronic hepatitis B. J Hepatol 26:1393-1395.
16. Ikeda K, Arase Y, Kobayashi M, Someya T, Saitoh S, Suzuki Y, Suzuki F, Tsubota A, Akuta N, Kumada H. 2003. Consistently low hepatitis B virus DNA saves patients from hepatocellular carcinogenesis in HBV-related cirrhosis. Intervirology 46:96-104.
17. Lai CL, Chien RN, Leung NWY, Chang TT, Guan R, Tai DI, Ng KY, Wu PC, Dent JC, Barber J, Stephenson SL, Gray DF. 1998. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 339:61-68.
18. Leung N. 2000. Liver disease-significant improvement with lamivudine. J Med Virol 61:380-385.
19. Leung NWY, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, Lim SG, Wu PC, Dent JC, Edmundson S, Condreay LD, Chien RN. 2001. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapy. Hepatology 33:1527-1532.
20. Liaw YF, Leung NWY, Chang TT, Guan R, Tai DI, Ng KY, Chien RN, Dent J, Roman L, Edmundson S, Lai CL. 2000. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 119:172-180.
21. Liaw YF, Sung JJY, Chow WC, Shue K, Keene O, Farrell G. 2003. Effect of lamivudine on disease progression and development of liver cancer in advanced chronic hepatitis B: A prospective double-blind placebo-controlled clinical trial [Abstract]. Hepatology 38(Suppl.):262A-263A.
22. Liaw YF, Chien RN, Yeh CT. 2004. No benefit to continue lamivudine therapy after emergence of YMDD mutations. Antiviral Therapy 9:257-262.
23. Ling R, Harrison TJ. 1999. Functional analysis of mutations conferring lamivudine resistance on hepatitis B virus. J Gen Virol 80:601-606.
24. Ling R, Mutimer D, Ahmed M, Boxall EH, Elias E, Dusheiko GM, Harrison TJ. 1996. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 3:711-713.
25. Lok ASF. 2004. Is it meaningful to pursue the safety of long-term lamivudine treatment in patients with chronic hepatitis B? [Correspondence, Reply]. Gastroenterology 126:1932-1933.
26. Lok ASF, Lai CL, Leung N, Yao GB, Cui ZY, Schiff ER, Dienstag JL, Heathcote EJ, Little NR, Griffiths DA, Gardner SD, Castiglia M. 2003. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 125:1714-1722.
27. Melegari M, Scaglioni PP, Wands JR. 1998. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 27:628-633.
28. Naoumov NV, Smith C, Williams R. 1996. Emergence and characterization of lamivudine resistant hepatitis B virus variant. Hepatology 24:282.
29. Nevens F, Main J, Honkoop P, Tyrrell DL, Barber J, Sullivan MT, Fevery J, De Man RA, Thomas HC. 1997. Lamivudine therapy for chronic hepatitis B: A six-month randomized dose-ranging study. Gastroenterology 113:1258-1263.
30. Okamoto H, Tsuda F, Sakugawa H, Sastrosoewignjo RI, Imai M, Miyakawa Y, Mayumi M. 1988. Typing hepatitis B virus by homology in nucleotide sequence: Comparison of surface antigen subtypes. J Gen Virol 69:2575-2583.
31. Ono-Nita SK, Kato N, Shiratori Y, Masaki T, Lan KH, Carriho FJ, Omata M. 1999. YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: A study by in vitro full-length viral DNA transfection. Hepatology 29:939-945.
32. Perrillo R, Schiff E, Yoshida E, Statler A, Hirsch K, Wright T, Gutfreund K, Lamy P, Murray A. 2000. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 32:129-134.
33. Peters M, Hann HW, Martin P, Heathcote E, Buggisch P, Moorat AE, Sullivan M, Kleber K, Ebrahimi R, Xiong S, Brosgart C. 2002. Adefovir dipivoxil alone and in combination with lamivudine suppresses lamivudine-resistant hepatitis B virus replication: 16 week interim analysis. J Hepatol 36:S6-S7.
34. Schalm SW. 1997. Clinical implications of lamivudine resistance by HBV. Lancet 349:3-4.
35. Schalm SW, Heathcote J, Cianciara J, Farrell G, Sherman M, Willems B, Dhillon A, Moorat A, Barber J, Gray DF. 2000. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: A randomised trial. Gut 46:562-568.
36. Sugauchi F, Orito E, Ichida T, Kato H, Sakugawa H, Kakumu S, Ishida T, Chutaputti A, Lai CL, Ueda R, Miyakawa Y, Mizokami M. 2002. Hepatitis B virus of genotype B with or without recombination with genotype C over the precore region plus the core gene. J Virol 76:5985-5992.
37. Suzuki Y, Kumada H, Ikeda K, Chayama K, Arase Y, Saitoh S, Tsubota A, Kobayashi M, Koike M, Ogawa N, Tanikawa K. 1999. Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection. J Hepatol 30:743-748.
38. Suzuki F, Tsubota A, Akuta N, Someya T, Kobayashi M, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Miyakawa Y, Kumada H. 2002. Interferon for treatment of breakthrough infection with hepatitis B virus mutants developing during long-term lamivudine therapy. J Gastroenterol 37:922-927.
39. Suzuki Y, Arase Y, Ikeda K, Saitoh S, Tsubota A, Suzuki F, Kobayashi M, Akuta N, Someya T, Miyakawa Y, Kumada H. 2003. Histological improvements after a three-year lamivudine therapy in patients with chronic hepatitis B in whom YMDD mutants did not or did develop. Intervirology 46:164-170.
40. Tassopoulos N, Hadziyannis S, Cianciara J, Rizzetto M, Schiff ER, Pastore G, Rutkiewicz V. 2001. Entecavir is effective in treating patients with chronic hepatitis B who have failed lamivudine therapy. Hepatology 34:340A.
41. Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DL. 1996. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 24:714-717.
42. Usuda S, Okamoto H, Iwanari H, Baba K, Tsuda F, Miyakawa Y, Mayumi M. 1999. Serological detection of hepatitis B virus genotypes by ELISA with monoclonal antibodies to type-specific epitopes in the preS2-region product. J Virol Methods 80:97-112.
43. Yuen MF, Sablon E, Hui CK, Yuan HJ, Decraemer H, Lai CL. 2001. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 34:785-791.